F104S c-Mpl responds to a transmembrane domain−binding thrombopoietin receptor agonist: Proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents

This publication has 19 references indexed in Scilit:

• Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
  Blood, 2009
• Xanthocillins as thrombopoietin mimetic small molecules
  Bioorganic & Medicinal Chemistry, 2005
• c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
  Blood, 2001
• The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat.
  1999
• Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia
  Proceedings of the National Academy of Sciences, 1999
• Efficiency of signalling through cytokine receptors depends critically on receptor orientation
  Nature, 1998
• Dissecting the thrombopoietin receptor: Functional elements of the Mpl cytoplasmic domain
  Proceedings of the National Academy of Sciences, 1997
• Mutagenesis Studies of the Human Erythropoietin Receptor
  Journal of Biological Chemistry, 1997
• Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer
  Blood, 1996
• Identification of a Critical Ligand Binding Determinant of the Human Erythropoietin Receptor
  Published by Elsevier ,1996